Maturitas Publishes a Clinical Guide on Low-Dose Vaginal Estrogens for Postmenopausal Vaginal Atrophy
Amsterdam, September 13, 2012 - Elsevier, a world-leading provider of scientific, technical and medical information products and services, announced today the publication of a position statement by the European Menopause and Andropause Society (EMAS) in the journal Maturitas. The society published a clinical guide on low-dose vaginal estrogens for postmenopausal vaginal atrophy also including a summary of recommendations.
Vaginal atrophy is common after menopause and adversely affects quality of life in one out of every two women. This guide provides the evidence for the clinical use of low-dose vaginal estrogens for this condition, focusing on publications since the 2006 Cochrane systematic review.The guide concludes that low-dose vaginal estrogensare effective and that there is no need for added progestogens for endometrial protection if topical estrogens are used in the recommended doses. With regard to duration of use, recommendations vary among patients, but vaginal atrophy is a chronic condition and will recur on cessation of treatment. Thus annual review would be prudent.
These and other recommendations presented in the EMAS clinical guide are published in the article: "EMAS clinical guide: Low-dose vaginal estrogens for postmenopausal vaginal atrophy" by Margaret Rees, Faustino R. Pérez-López, Iuliana Ceasu, Herman Depepyre, Tamer Erel, Irene Lambrinoudaki, Karin Schenck-Gustafsson, Tommaso Simoncini, Yvonne van der Schouw, and Florence Tremollieres (10.1016/j.maturitas.2012.06.009). The article appears in Maturitas Volume 73, Issue 2 (October 2012) published by Elsevier.
# # #
About the European Menopause and Andropause Society (EMAS)
The EMAS promotes the study of midlife health through its journal, congresses, schools and website and encourages the exchange of research and professional experience between members. Using a range of activities and through its affiliates, the EMAS aims to guarantee and provide the same standard of education and information throughout Europe on midlife health in both genders. Recognizing the issues arising from increased longevity, the society also provides articles, patient information, web resources, and referrals for healthcare providers in the field and keeps its members up-to-date.
For more information go to: http://www.emas-online.org/
Maturitas is an international multidisciplinary peer reviewed scientific journal of midlife health and beyond, publishing original research, reviews, consensus statements and guidelines. The scope encompasses all aspects of postreproductive health in both genders ranging from basic science to health and social care. www.maturitas.org.
Elsevier is a global information analytics business that helps scientists and clinicians to find new answers, reshape human knowledge, and tackle the most urgent human crises. For 140 years, we have partnered with the research world to curate and verify scientific knowledge. Today, we’re committed to bringing that rigor to a new generation of platforms. Elsevier provides digital solutions and tools in the areas of strategic research management, R&D performance, clinical decision support, and professional education; including ScienceDirect, Scopus, SciVal, ClinicalKey and Sherpath. Elsevier publishes over 2,500 digitized journals, including The Lancet and Cell, 39,000 e-book titles and many iconic reference works, including Gray's Anatomy. Elsevier is part of RELX Group, a global provider of information and analytics for professionals and business customers across industries. www.elsevier.com
+31 20 485 3323